Best Immunotherapy Companies in Maryland, United States
The 67 best Immunotherapy companies in Maryland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novavax.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Maryland
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Novavax Developer of novel vaccines for the treatment of infectious diseases 83Product top 14%Patents top 17%Funding top 22%Innovation top 23% All 13 signals ▾Producttop 14% Patentstop 17% Fundingtop 22% Innovationtop 23% Partnerstop 26% Markettop 28% Moattop 29% Fin. healthtop 32% Globaltop 35% Growthtop 37% Newstop 40% Techtop 41% Talentbottom 48% Product: 4 distinct product lines · Company stage: Public Patents: 599 patents matched (strict assignee match) · 193 filings since 2022 vs 135 in 2017-21 rank vs industry peers · Fliar Intelligence Index 83/100 | $2.7B | 33 mo ago | 184 | John Jacobs President | Public | 589 patents Formulating viral and bacterial vaccines with saponin adjuvants and nanoparticle delivery. | 2 launchs · 2 partnerships |
| 2 | Emergent BioSolutions Developer of vaccines primarily for virus infections | $491M | 45 mo ago | 1,600 1,600 → 1,366 (-15%) | — | Public | 29 patents Vaccines and monoclonal antibodies targeting high‑risk biothreat pathogens | 1 award |
| 3 | Viela Bio Developer of biologics for treating severe inflammation and autoimmune diseases | $357M | 84 mo ago | 170 | — | Acquired | 242 patents Immunomodulatory antibody/scaffold therapeutics targeting CD40L, CD19, Ilt7 for autoimmune diseases | — |
| 4 | Precigen Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious… | $234M | 66 mo ago | 25 | Thomas Reed Founder | Public | 262 patents Gene and cell therapy platforms for viral vaccines, CAR‑T, and protein deficiency treatments. | — |
| 5 | Sanaria Developer of whole-parasite malaria vaccines for infectious diseases 48Funding top 23%Patents top 33%Moat top 41%Innovation top 46% All 8 signals ▾Fundingtop 23% Patentstop 33% Moattop 41% Innovationtop 46% Growthtop 47% Marketbottom 44% Techbottom 44% Globalbottom 37% Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $188M | 9 mo ago | 77 | — | Funding Raised | 133 patents Live attenuated malaria sporozoite vaccines and cryogenic parasite/egg preservation technologies. | — |
| 6 | Clasp Therapeutics Developer of T cell therapeutics for the treatment of cancer | $150M | 27 mo ago | — | Shibin Zhou Co-Founder | Series A | — | 1 award |
| 7 | MacroGenics Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | 87 mo ago | 339 339 → 378 (+12%) | Scott Koenig President and CEO | Public | 1,258 patents Therapeutic antibodies and ADCs targeting immune checkpoints (PD‑1, CD3, ADAM9, B7‑H3). | — |
| 8 | Immunomic Therapeutics Vaccines for allergy, cancer and infectious disease. 57Funding top 24%Growth top 28%Product top 30%Innovation top 34% All 9 signals ▾Fundingtop 24% Growthtop 28% Producttop 30% Innovationtop 34% Moattop 39% Techbottom 44% Marketbottom 37% Globalbottom 37% Newsbottom 21% Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $98M | 12 mo ago | 51 | — | Series B | — | — |
| 9 | Sensei Biotherapeutics Developer of immunotherapies for the treatment of cancer | $94M | 65 mo ago | 27 | John Celebi Chief Executive Officer | Public | 19 patents Immuno‑oncology antibodies and bispecifics targeting the VISTA checkpoint for cancer therapy | — |
| 10 | DEKA Biosciences Developer of therapeutics for cancer and inflammatory diseases | $76M | 40 mo ago | 30 | Pavel Khrimian Co-founder & CBO | Series B | 104 patents Engineered IL-10 cytokine fusions to mitigate cytokine release syndrome in CAR‑T/bi‑specific immunotherapies | — |
| 11 | Georgiamune Developer of immunotherapeutics to treat cancer and autoimmune diseases | $75M | 34 mo ago | 14 14 → 30 (+114%) | Samir Khleif Founder & CEO | Series A | 122 patents Patents concentrated in chemistry & materials | — |
| 12 | Gliknik Discovering and developing innovative biologics for immune disorders and cancers 22Funding top 21%Moat top 21%Product top 25%Patents top 31% All 9 signals ▾Fundingtop 21% Moattop 21% Producttop 25% Patentstop 31% Innovationtop 33% Globalbottom 36% Newsbottom 22% Marketbottom 20% Techbottom 16% Funding: Raised $60.3M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 246 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $60M | 10 mo ago | 6 | — | Series C | 246 patents Engineered multimeric Fc fusion proteins for enhanced complement binding and immune activation | — |
| 13 | Iomai Corporation Online dissertation writing help, advice, and resources for graduate students | $54M | 281 mo ago | 110 | Gerd Zettlmeissl CEO | Acquired | 14 patents Transdermal vaccine delivery systems and LT‑STa fusion protein skin immunization technologies. | — |
| 14 | OncoC4 Developer of immunotherapy for cancer patients 62Patents top 17%Innovation top 21%Funding top 28%Moat top 33% All 7 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 28% Moattop 33% Globalbottom 43% Marketbottom 42% Newsbottom 34% Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $52M | 8 mo ago | 41 | — | Series B | 128 patents Immune checkpoint antibody therapeutics targeting CTLA‑4 and CD80/86 for cancer. | 1 job opening |
| 15 | PharmAthene Developing anthrax vaccine designed to protect against inhalational anthrax. | $50M | 187 mo ago | 15 | Vipin Garg CEO | Public | 29 patents Biodefense vaccines and recombinant butyrylcholinesterase therapeutics for anthrax and nerve agents | — |
| 16 | Abvacc Developer of vaccines and therapeutics to treat infectious diseases 35Funding top 30%Moat top 38%Patents top 43%Innovation top 50% All 7 signals ▾Fundingtop 30% Moattop 38% Patentstop 43% Innovationtop 50% Talentbottom 49% Marketbottom 37% Globalbottom 31% Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $46M | 12 mo ago | — | M Aman Founder | Funding Raised | 6 patents Targeted bacterial infection immunotherapies using bacteriolysin domains and toxin-derived peptide vaccines | — |
| 17 | Zyngenia Develops monoclonal antibody (mAb)-based drugs to treat cancer, inflammation and autoimmune disorders | $43M | 165 mo ago | 6 | Carlos Barbas Founder | Series B | 37 patents Engineered multispecific peptide‑antibody complexes targeting EGFR and Ang‑2 for cancer therapy | — |
| 18 | VLP Therapeutics Developer of therapeutic vaccines for the treatment of cancer, infectious and CNS disease | $37M | 34 mo ago | 15 | Wataru Akahata Co-Founder & CEO | Series A | — | — |
| 19 | NexImmune Developer of immunotherapeutics for cancer | $36M | 88 mo ago | 69 | — | Public | 92 patents Patents concentrated in health & consumer products | — |
| 20 | Cellective Therapeutics Biotech research company working on B Cell Research for cancer and autoimmune diseases, acquired by MedImmune… | $28M | 260 mo ago | — | Pascal Soriot CEO | Acqui-Hired | — | — |
| 21 | Antidote Therapeutics Developing nicotine-blockers to treat diseases caused by nicotine and addiction | $22M | 14 mo ago | 3 | Matthew Kalnik Founder & CEO | Funding Raised | — | — |
| 22 | Profectus BioSciences Using proprietary discovery engine to develop vaccines against viral infectious diseases and their associated… | $19M | 121 mo ago | 3 | — | Deadpooled | 41 patents Engineered Isfahan viral vectors for gene therapy and recombinant protein production | — |
| 23 | Vaccinogen Exploring video game history, developers, and software providers | $17M | 127 mo ago | 24 24 → 12 (-50%) | — | Public | 6 patents Personalized autologous tumor antigen vaccines for cancer immunotherapy | — |
| 24 | Cytimmune Multifunctional and tumor-targeted cancer therapies | $15M | 65 mo ago | 1 | Lawrence Tamarkin Co-Founder | Early Stage | — | — |
| 25 | mRNA Developer of therapeutics for the treatment of cancer, rare diseases, and others | $12M | 50 mo ago | 9 | Dong Shen CEO | Series A | — | — |
| 26 | Benevir Innovative medicine, therapies, and medical technology for global healthcare solutions | $11M | 103 mo ago | 10 | — | Acquired | — | — |
| 27 | Biological Mimetics Innovating biomedical solutions to combat global infections and improve public health | $11M | 24 mo ago | — | Peter Nara CEO | Funding Raised | 39 patents Inactivated bacterial/viral vaccine formulations and multi-chamber point-of-care pathogen detection devices | — |
| 28 | VerImmune Developer of vaccines for the treatment of cancer | $10M | 13 mo ago | 7 | John Troyer Founder & COO | Seed | 36 patents Virus-like particle-based cancer immunotherapies that redirect antigen-specific immune responses | 1 award |
| 29 | PathoVax Prophylactic vaccine against all 15 oncogenic human papillomavirus. | $10M | 73 mo ago | 3 | Travis Stiles Co-Founder and Interim CEO | Deadpooled | 11 patents Design of chimeric virus-like particle platforms for targeted vaccine and immunotherapy applications | — |
| 30 | OncoSTING Developer of immunotherapy for bladder cancer | $5M | 6 mo ago | 3 | William Bill Bishai Co-Founder | Funding Raised | — | — |
| 31 | Integrated BioTherapeutics Vaccines and Antibodies for bacterial & viral infections | $5M | 37 mo ago | 43 | Javad Aman CEO | Series A | 82 patents Broad-spectrum antiviral and antibacterial immunotherapies using engineered antibodies and peptide toxins. | 1 job opening · 1 launch |
| 32 | Ibex Biosciences Developer of antibody and gene therapy technologies for oncology, inflammation, autoimmune disease and… | $4M | 16 mo ago | 11 | — | Seed | — | — |
| 33 | Cellicure Developer of cell-based immunotherapies for cancer treatment | $4M | 49 mo ago | 3 | Q Li Co-Founder & CEO | Series A | 6 patents Genetically engineered immune cell therapies (e.g., CAR‑T, modified lymphocytes) | — |
| 34 | Immune Therapeutics Specialty pharma developing immunotherapies such as Low Dose Naltrexone (LDN) | $4M | 46 mo ago | 4 | — | Public | — | — |
| 35 | Irazu Oncology Developer of vaccines for colorectal cancer patients | $3M | 30 mo ago | 2 | Marco Chacon Founder | Seed | 5 patents Engineered Salmonella typhi live bacterial vectors for cancer antigen vaccine delivery. | — |
| 36 | Northwest Biotherapeutics Developer of dendritic cell-based vaccines for prostate and brain cancer | $2M | 18 mo ago | 22 | — | Public | 250 patents Dendritic cell-based cancer immunotherapies and checkpoint inhibitor combination treatments. | — |
| 37 | MedImmune Biologic R&D for oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic diseases | $2M | 93 mo ago | 3,000 | Speck Loe CEO | Acquired | 3,933 patents Therapeutic antibodies, bispecifics, and ADCs targeting immune receptors for inflammation and cancer | — |
| 38 | A&G Pharmaceutical Theranostics company developing targeted therapeutics and companion diagnostics for personalized cancer care | $2M | 16 mo ago | 12 | Ginette Serrero Co - Founder & CEO & Board Director | Series A | — | — |
| 39 | Nanocan Developer of therapeutic solutions for cancer treatment | $1M | 14 mo ago | 5 | Eric Broyles Founder & CEO | Series A | — | — |
| 40 | Medigen Developing safe, effective vaccines against emerging diseases for lifelong immunity | $992K | 177 mo ago | 36 | — | Funding Raised | 60 patents Virus-like particle platforms for RNA virus vaccine development | — |
| 41 | NeuImmune Developer of vaccine and therapeutics for infectious diseases | $574K | 35 mo ago | — | Nathan Lewis Co-Founder | Funding Raised | — | — |
| 42 | Immage Biotherapeutics DNA viral vaccine construct targeted to tumors that expresses the Melanoma antigen family – A (MAGE-A)… | $500K | 123 mo ago | 4 | — | Deadpooled | — | — |
| 43 | HepC Developer of antiviral biologic products | $400K | — | — | Thomas Bakacs CEO | Funding Raised | — | — |
| 44 | Paradigm Shift Therapeutics E-commerce platform accelerating progress in Southeast Asia through commerce and technology | $350K | 117 mo ago | 4 | Kate Farrell Co-Founder & CEO | Funding Raised | — | — |
| 45 | TeraImmune Developer of cell therapies for treating different diseases | $225K | 98 mo ago | 10 | Jihoon Park Co-Founder & COO | Acquired | 11 patents Cellular immunotherapy using cord‑blood‑derived regulatory T cells and enhanced stem‑cell combos for dermatitis | — |
| 46 | Adventris Developer of immuno-therapeutics for cancer treatment | $125K | 36 mo ago | 2 | William Collis Co-Founder | Seed | — | — |
Top 12 Immunotherapy companies in Maryland
#1
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees$187.8Mraised▾
Developer of whole-parasite malaria vaccines for infectious diseases. The company is developing protective vaccines against malaria and plasmodium falciparum infection in humans.
- Sep 2025Grant (prize money)$2M
- Sep 2025Grant (prize money)$5.9M
- Jul 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$988.8K
#2
Series C · Baltimore, Maryland · founded 2007 · 6 employees$60.3Mraised▾
Discovering and developing innovative biologics for immune disorders and cancers. The company focuses on modulating the immune system to create new treatment options for autoimmune diseases and cancers. They are advancing multiple drugs through clinical trials, including recombinant Fc fusion proteins designed to mimic or inhibit specific immune pathways. Their approach involves a team of talented scientists, board members, scientific advisors, and a network of global thought leaders. They aim to make a significant difference in the lives of individuals with immune disorders through innovative drug discovery and development. Their expertise lies in biologics, clinical trials, drug design, protein production, purification, and analysis, targeting autoimmune diseases and cancers.
- Aug 2025Series C$11M
- Nov 2024Series C$5.3M
- Jul 2023Series C$5.4M
- Jun 2021Series C$11.5M
#3
Series B · Rockville, Maryland · founded 2020 · 41 employees$52.3Mraised▾
Developer of immunotherapy for cancer patients. The lead product, CD24Fc reduces disease progression to death or respiratory failure. The lead candidate ONC-392 is a next-generation anti-CTLA-4 antibody, other candidates targeting cancer cells through chimeric antigen receptors T cells, bi-specific antibodies, and antibody-drug conjugates cells.
- Oct 2025Series B$50M
- Apr 2020Grant (prize money)$2.3M
#4
Series B · Rockville, Maryland · founded 2005 · 51 employees$97.9Mraised▾
Immunomic Therapeutics develops lysosomal-associated membrane protein-based vaccines for the treatment of allergy and cancer. The company has partnered with Astellas to develop vaccines for Japnese red cedar (Phase 1), peanut allergy (Phase 1). Its immunology pipeline includes AST-VAC1 to treat acute myeloid leukemia (AML) (Phase 2); LAMP-Vax + pp64 DC therapy for brain cancer (Phase 1); ATTAC-II clinical trial (Phase II), etc.
- May 2025Series B$6.5M
- Jan 2024Series B$3M
- Jan 2021Series B$77.7M
- Jul 2018Series A$314.5K
#5
Funding Raised · Rockville, Maryland · founded 2023$45.5Mraised▾
Developer of vaccines and therapeutics to treat infectious diseases. The company's pipeline includes product candidates for the prevention and treatment of bacterial and viral infections. It has a bacterial program that primarily focuses on staphylococcal infections by targeting a variety of virulence factors such as toxins and critical enzymes produced by S. aureus. The company has also developed a large collection of potently neutralizing fully human and macaque-human chimeric antibody therapeutics and vaccines for filoviruses and the Nipah virus.
- May 2025Grant (prize money)$1.3M
- May 2025Grant (prize money)$1.3M
- Apr 2025Grant (prize money)$6.6M
- Feb 2025Grant (prize money)$3M
#6
Funding Raised · Baltimore, Maryland · founded 2018 · 3 employees$5Mraised▾
Developer of immunotherapy for bladder cancer. The lead candidate OS-101 is a STING agonist and BCG-based immunotherapy for bladder cancer that trigger proinflammatory innate immune responses against tumors.
- Dec 2025Grant (prize money)$2.2M
- Jun 2024Grant (prize money)$270.2K
- Jun 2022Grant (prize money)$256K
- Sep 2021Grant (prize money)$2.2M
#7
Funding Raised · Gaithersburg, Maryland · founded 2017 · 3 employees$22.4Mraised▾
Developing nicotine-blockers to treat diseases caused by nicotine and addiction. The company is focused on creating first-in-class treatments targeting rare vascular diseases and addiction through proprietary treatments. They leverage a global collaborative drug research and development network, incorporating expertise from academic labs, clinical research groups, biotechnology companies, and biopharmaceutical consultants. Their pipeline includes a fully human, anti-nicotine monoclonal antibody and a nicotine-degrading enzyme, both in development. The company aims to address the global health crisis related to smoking by providing innovative therapeutic solutions. This involves immunotherapeutic approaches, clinical research, and biopharmaceutical drug development.
- Apr 2025Grant (prize money)$13.1M
- Sep 2017Grant (prize money)$8.5M
- Sep 2017Conventional Debt$200K
- Aug 2017Conventional Debt$432.3K
#8
Public · Gaithersburg, Maryland · founded 1987 · 184 employees$2.7Braised▾
Developer of novel vaccines for the treatment of infectious diseases. Its pipeline includes a vaccine for respiratory syncytial virus infection, coronavirus, malaria, ebola, and seasonal quadrivalent vaccines for influenza. It uses recombinant nanoparticles and adjuvant technology.
- Sep 2023Post IPO$84.5M
- Jul 2020Grant (prize money)$1.6B
- Jun 2020Post IPO$200M
- Jun 2020Grant (prize money)$60M
#9
Seed · Baltimore, Maryland · founded 2019 · 7 employees$10.1Mraised▾
Developer of vaccines for the treatment of cancer. The company is developing Anti-tumor Immune Redirection (AIR) a therapy that redirects the pre-existing immune memory from childhood vaccines or infections to fight cancer. They have developed a papillomavirus nanoparticle conjugated with viral antigens to treat cancer.
- Apr 2025Grant (prize money)$470.4K
- Sep 2024Seed$4.5M
- Sep 2023Seed$3.1M
- Jul 2022Seed$2.5M
#10
Seed · Cumberland, Maryland · founded 2015 · 11 employees$4.2Mraised▾
Developer of antibody and gene therapy technologies for oncology, inflammation, autoimmune disease and retinal disease. The pipeline includes therapeutic antibody programs to treat various inflammatory conditions and oncology, gene therapies for Gaucher's disease and other metabolic storage disorder conditions, and stem cell therapies for retinal regeneration and cardiac muscle regeneration.
- Feb 2025Seed$70K
- Feb 2025Conventional Debt—
- Jan 2020Seed$2.4M
- Sep 2017Grant (prize money)$277.8K
#11
Series A · Columbia, Maryland · founded 2000 · 12 employees$2.1Mraised▾
Theranostics company developing targeted therapeutics and companion diagnostics for personalized cancer care. They are focused on developing monoclonal antibodies against cancer-specific targets for novel therapeutic and diagnostic products. Their approach selectively restricts the drivers of tumor growth, enabling more personalized and effective care for cancer patients. They harness the power of antibodies to selectively recognize and bind to the specific cell-surface biomarkers that distinguish diseased cells from normal cells. They are engineering a new generation of therapeutics that selectively strike the causes of tumor growth, while concurrently developing companion diagnostic tests that reliably reveal the specific cancer, identify patients that will respond to the associated targeted therapy, predict recurrence, and monitor response to treatment. They develop linked diagnostic-therapeutic products based on cancer-specific biomarkers discovered through its proprietary platform, enabling more effective individualized treatment. Their scientific leadership includes world-leading researchers in cell biology, immunology, and growth factor research, providing a strong foundatio
- Feb 2025Grant (prize money)$2M
- Sep 2018Grant (prize money)$2M
- Mar 2017Grant (prize money)$1.2M
- Sep 2013Grant (prize money)$138.8K
#12
Series A · Rockville, Maryland · founded 2020$150Mraised▾
Developer of T cell therapeutics for the treatment of cancer. The company is developing next-generation T cell engagers that target tumor-specific oncogenic driver mutations across hard-to-treat cancers.
- Mar 2024Series A$150M
- Oct 2023Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology in Maryland is moving
A read on the academic research around Immunology in Maryland — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 83 papers.
- University of Maryland, Baltimore65
- University of Maryland, College Park11
- University of Maryland Medical Center7
- Virginia–Maryland College of Veterinary Medicine5
- Maryland University of Integrative Health3
- Immune system11
- T cell5
- Immunotherapy4
- Immune checkpoint3
- Cytokine3
- Immunotherapy1→14
- Immune system3→13
- Cancer research1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.